Recent Finacing
Recent Raise
FLX Bio is a South San Francisco biopharma developing orally-available small-molecule immuno-oncology and oncology drugs, advancing CCR4 antagonist FLX475 and FLT3/CDK4/6 inhibitor FLX925 through preclinical and Phase 1 studies.
